Insight Molecular Diagnostics Inc. (IMDX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation) is a diagnostics technology company focused on organ transplant rejection testing (GraftAssure family) and oncology therapy selection/monitoring. The company operates a CLIA-certified laboratory in Franklin, Tennessee, and R&D labs in Nashville, Tennessee, and Göttingen, Germany. In June 2025, the company changed its name and trading symbol to IMDX and relocated its headquarters to Nashville.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $32,000 | $2,138,000 |
| Net Loss | $(4,290,000) | $(6,671,000) |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.26) |
| Cash and Cash Equivalents | $28,201,000 | $11,583,000 |
| Total Assets | $40,427,000 | $25,756,000 |
| Total Liabilities | $51,118,000 | $57,220,000 |
| Accumulated Deficit | $(405,051,000) | $(400,761,000) |
| Operating Cash Flow | $(7,639,000) | $(5,839,000) |
| Financing Cash Flow | $24,698,000 | $28,558,000 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue dropped 99% to $32,000 from $2.1 million in Q1 2025. This is primarily due to the completion of a major Laboratory Services project and a strategic shift toward commercializing kitted transplant tests (GraftAssureIQ/Dx).
- Expense Increases:
- R&D Expenses: Increased 69% to $4.95 million, driven by clinical trials for GraftAssureDx, professional fees, and personnel costs.
- Sales & Marketing: Increased 99% to $2.4 million due to ramp-up activities for the transplant business.
- Contingent Consideration Gain: The company recorded a non-cash gain of $5.9 million due to a decrease in the fair value of contingent consideration liabilities (primarily related to the Chronix acquisition). This significantly reduced the net loss compared to the prior year.
- Liquidity Improvement: Cash balances increased from $11.6 million to $28.2 million following a registered direct offering in February 2026 that raised approximately $24.6 million in net proceeds.
Guidance, Outlook, and Risks
- Strategic Focus: Management is prioritizing the commercialization of the GraftAssure family of assays for organ transplant rejection monitoring. On March 25, 2026, the company submitted a data package to the FDA seeking marketing authorization for GraftAssureDx.
- Capital Requirements: The company expects to continue incurring operating losses and negative operating cash flows for the foreseeable future. Management believes current cash resources are sufficient to meet operating requirements for at least the next 12 months.
- Key Risks:
- Regulatory Approval: Success depends on obtaining FDA marketing authorization and Medicare reimbursement for clinical tests.
- Concentration Risk: Significant dependency on Bio-Rad Laboratories for instrument supply, reagents, and commercialization collaboration. Bio-Rad is also a significant investor.
- Contingent Liabilities: The company holds approximately $38 million in contingent consideration liabilities related to past acquisitions (IGI and Chronix), which could require future cash payments if revenue milestones are met.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $28.2 million cash balance against projected burn rates, given the high R&D spend ($4.95M/quarter) and lack of significant recurring revenue.
- Regulatory Timeline: Monitor the status of the GraftAssureDx FDA submission filed in March 2026 and the timeline for potential marketing authorization.
- Bio-Rad Partnership: Assess the terms and stability of the strategic collaboration with Bio-Rad, including the royalty structure and the partner's commitment to commercialization.
- Contingent Consideration: Review the assumptions used to value the $38 million contingent liability and the likelihood of future payouts based on revenue milestones.
- Revenue Transition: Evaluate the ability to replace the lost Laboratory Services revenue with sales of GraftAssureIQ (RUO) and future GraftAssureDx (IVD) kits.